{
    "clinical_study": {
        "@rank": "161655", 
        "brief_summary": {
            "textblock": "The objective of this Phase III, randomized, double-blind, placebo-controlled study in\n      patients with immunologic deficiency is to determine the effect of Isoprinosine in producing\n      an immuno-restorative response within the study observation period (including the 2-month\n      period following cessation of the 28 days of treatment), measured by one or more of the\n      following immunological parameters:\n\n        -  Increase in natural killer (NK) cell activity.\n\n        -  Increase in total T-cells (OKT-11).\n\n        -  Increases in absolute number and percentage of T-helper cells (OKT-4)."
        }, 
        "brief_title": "The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease", 
        "condition": [
            "Lymphatic Disease", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Lymphatic Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction\n             and severe gastric ulcer.\n\n          -  Lymphoid malignancy.\n\n          -  Infectious mononucleosis caused by cytomegalovirus or Epstein-Barr virus.\n\n          -  Heart disease (especially if receiving cardiac glycosides).\n\n          -  Hemophilia.\n\n        Patients with the following are excluded:\n\n          -  Kaposi's sarcoma or overt opportunistic infections as follows:\n\n          -  Candida albicans, Pneumocystis carinii, Herpes simplex, Cryptococcus neoformans,\n             Histoplasma capsulatum, Mycobacterium avium-intracellulare, Toxoplasma gondii,\n             Legionella, Cryptosporidium, Isospora, and Papovavirus.\n\n          -  Active evidence of infectious mononucleosis caused by Epstein-Barr virus (EBV) or\n             cytomegalovirus (CMV) as determined by heterophil test (EBV) or cell culture (CMV).\n\n          -  History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal\n             dysfunction, and severe gastric ulcer.\n\n          -  Critical illness.\n\n          -  Condition requiring hospitalization.\n\n          -  Women of childbearing age are excluded.\n\n          -  Hemophilia.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Steroids.\n\n          -  Cytotoxic immunosuppressive agents.\n\n          -  Antiviral medicine.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiotherapy.\n\n        Patients who have unexplained immunodepression and are at risk of developing AIDS.\n\n          -  Patients with prolonged generalized lymphadenopathy for 3 or more months (greater\n             than 1 cm at two or more noncontiguous sites).\n\n        IV drug abuse."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002296", 
            "org_study_id": "008C", 
            "secondary_id": "ISO-106-USA"
        }, 
        "intervention": {
            "intervention_name": "Inosine pranobex", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Inosine Pranobex"
        }, 
        "keyword": [
            "T-Lymphocytes", 
            "Immune Tolerance", 
            "Inosine Pranobex", 
            "Killer Cells", 
            "T-Lymphocytes, Helper-Inducer", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Laguna Hills", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92656"
                }, 
                "name": "Newport Pharmaceuticals International Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multi-Center Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002296"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Newport Pharmaceuticals International", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1989"
    }, 
    "geocoordinates": {
        "Newport Pharmaceuticals International Inc": "33.599 -117.699"
    }
}